https://www.selleckchem.com/pr....oducts/lenalidomide-
to secondary progressive MS, and DMT effectiveness uncertainty. Patient centred decision aids should include information about first and consecutive treatment decisions.Dermatographism is a disorder of unknown etiology that results in inducible hives from environmental stimuli. Here we report the first known case of dermatographism associated with ocrelizumab in a patient with relapsing remitting multiple sclerosis. The patient presented with pruritic linear raised rash approximately two weeks after her first infusion with oc